stockrow
Saturday 7 November 2026
Export CRVO’s income statement to Excel — free account
CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- +8.57%
- Free cash flow
- −6.20%
Quarter to June 2026, against a year earlier
1.41
0.04
−2.76%
Follow CRVO
Alert me
CervoMed Inc. (CRVO) P/E ratio
CervoMed Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 20.5× (October 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 20.5×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | n/m |
| IGC IGC Pharma, Inc. compare | n/m |
| CVM Cel-Sci Corporation compare | n/m |
| MCRB Seres Therapeutics, Inc. compare | n/m |
| CELU Celularity, Inc. compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | n/m |
| NXTC NextCure, Inc. compare | n/m |
| CRVO CervoMed Inc. | n/m |
| FLNA Cassava Sciences, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)